Cytoskeletal active agents for glaucoma therapy
US6110912A · kind A · utility
110Cited by
2References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 11, 1998 |
| Grant date | Aug 29, 2000 |
| Priority date | — |
| Expiry date | Feb 11, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.